Targeted Prophylaxis Effective in Post-Prostate Biopsy Sepsis

This article originally appeared here.
Share this content:
Targeted Prophylaxis Effective in Post-Prostate Biopsy Sepsis
Targeted Prophylaxis Effective in Post-Prostate Biopsy Sepsis

TUESDAY, July 21, 2015 (HealthDay News) -- For patients undergoing transrectal prostate biopsy, targeted prophylaxis is similarly effective to empirical prophylaxis for prevention of post-biopsy sepsis, according to a study published in the August issue of The Journal of Urology.

Michael A. Liss, M.D., from the University of Texas Health Science Center San Antonio, and colleagues compared the effectiveness of targeted prophylaxis with empirical prophylaxis for preventing sepsis after transrectal prostate biopsy. Rectal cultures were performed before transrectal prostate biopsy, and antibiotic sensitivities of Escherichia coli were used to guide antibiotic selection in the targeted prophylaxis group. Data were included for 5,355 prostate biopsy procedures; targeted prophylaxis was used in 34 percent and empirical prophylaxis in 66 percent of procedures.

The researchers found that post-biopsy sepsis incidence was 0.52 percent overall. The incidence of sepsis was 0.44 and 0.56 percent in the targeted prophylaxis and empirical prophylaxis groups, respectively (P = 0.568). On rectal culture, the prevalence of ciprofloxacin-resistant E. coli was 25 percent. Most patients on targeted prophylaxis in whom sepsis developed used a prophylactic antibiotic to which the sepsis-causing bacteria were sensitive (seven of eight cases).

"The targeted prophylaxis protocol enabled physicians to avoid using more than one broad-spectrum empirical antibiotic while simultaneously achieving an overall rate of sepsis similar to the rate seen with empirical prophylaxis," the authors write.

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »